Ultragenyx Pharmaceutical RARE Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxLiabilitiesNet.
The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's deferred tax assets?
- Ultragenyx Pharmaceutical (RARE) reported deferred tax assets of $30M in Q1 2026.
- How has Ultragenyx Pharmaceutical's deferred tax assets changed year-over-year?
- Ultragenyx Pharmaceutical's deferred tax assets decreased by 0.2% year-over-year, from $30.06M to $30M.
- What is the long-term trend for Ultragenyx Pharmaceutical's deferred tax assets?
- Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's deferred tax assets has grown at a -2.1% compound annual growth rate (CAGR), from $33.31M to $30M.
- What does deferred tax assets mean?
- Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.